Publication date: 2026 Source: Gastro Hep Advances, Volume 5, Issue 12 Author(s): Kyle Staller, Jenna Clukey, Elizabeth N. Madva, Brian C. Healy, Minyi Lee, Manish K. Gala
CYP2D6 Metabolizer Status Does Not Predict Response or Tolerability of Low-Dose Nortriptyline for Irritable Bowel Syndrome With Diarrhea. // Gastro Hep Advances. – URL: https://www.sciencedirect.com/science/article/pii/S2772572326002323?dgcid=rss_sd_all
CYP2D6 Metabolizer Status Does Not Predict Response or Tolerability of Low-Dose Nortriptyline for Irritable Bowel Syndrome With Diarrhea. Gastro Hep Advances. https://www.sciencedirect.com/science/article/pii/S2772572326002323?dgcid=rss_sd_all
“CYP2D6 Metabolizer Status Does Not Predict Response or Tolerability of Low-Dose Nortriptyline for Irritable Bowel Syndrome With Diarrhea.” Gastro Hep Advances.
@article{article46572,
title = {CYP2D6 Metabolizer Status Does Not Predict Response or Tolerability of Low-Dose Nortriptyline for Irritable Bowel Syndrome With Diarrhea},
journal = {Gastro Hep Advances},
url = {https://www.sciencedirect.com/science/article/pii/S2772572326002323?dgcid=rss_sd_all}
}